Last reviewed · How we verify

Nalbuphine and morphine

National Taiwan University Hospital · FDA-approved active Small molecule

Nalbuphine and morphine are opioid agonists that bind to opioid receptors in the central nervous system to produce analgesia and pain relief.

Nalbuphine and morphine are opioid agonists that bind to opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Moderate to severe pain management, Postoperative pain.

At a glance

Generic nameNalbuphine and morphine
SponsorNational Taiwan University Hospital
Drug classOpioid analgesic combination
TargetOpioid receptors (mu, kappa, delta)
ModalitySmall molecule
Therapeutic areaPain management
PhaseFDA-approved

Mechanism of action

Nalbuphine is a mixed opioid agonist-antagonist that acts primarily as a kappa receptor agonist and mu receptor antagonist, while morphine is a mu opioid receptor agonist. When used in combination, they work synergistically to provide pain relief through activation of opioid receptors in the brain and spinal cord, modulating pain perception and transmission.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: